Remove 2002 Remove Healthcare Provider Remove Side effects
article thumbnail

The State of the Union in Cancer Innovation

PM360

Our clinical data is encouraging and supports potential registrational paths based upon its molecular design focused upon selectivity for cancer-relevant T cells and decreased side effects. What Is Your Company Currently Working On? Preliminary data are expected in 2023.